gcm2 Promotes Glial Cell Differentiation and Is Required with glial cells missing for Macrophage Development in Drosophila  by Alfonso, Teresa B & Jones, Bradley W
Developmental Biology 248, 369–383 (2002)
doi:10.1006/dbio.2002.0740gcm2 Promotes Glial Cell Differentiation and Is
Required with glial cells missing for Macrophage
Development in Drosophila
Teresa B. Alfonso and Bradley W. Jones1
Molecular Neurobiology Program, Skirball Institute of Biomolecular Medicine, and Department
of Pharmacology, New York University School of Medicine, New York NY 10016
glial cells missing (gcm) is the primary regulator of glial cell fate in Drosophila. In addition, gcm has a role in the
differentiation of the plasmatocyte/macrophage lineage of hemocytes. Since mutation of gcm causes only a decrease in
plasmatocyte numbers without changing their ability to convert into macrophages, gcm cannot be the sole determinant of
plasmatocyte/macrophage differentiation. We have characterized a gcm homolog, gcm2. gcm2 is expressed at low levels in
glial cells and hemocyte precursors. We show that gcm2 has redundant functions with gcm and has a minor role promoting
glial cell differentiation. More significant, like gcm, mutation of gcm2 leads to reduced plasmatocyte numbers. A deletion
removing both genes has allowed us to clarify the role of these redundant genes in plasmatocyte development. Animals
deficient for both gcm and gcm2 fail to express the macrophage receptor Croquemort. Plasmatocytes are reduced in number,
but still express the early marker Peroxidasin. These Peroxidasin-expressing hemocytes fail to migrate to their normal
locations and do not complete their conversion into macrophages. Our results suggest that both gcm and gcm2 are required
together for the proliferation of plasmatocyte precursors, the expression of Croquemort protein, and the ability of
plasmatocytes to convert into macrophages. © 2002 Elsevier Science (USA)
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The glial cells missing gene (gcm) is the primary regulator
of glial cell determination in Drosophila. It encodes a
transcription factor that is transiently expressed in all
embryonic glia, except for the midline/mesectoderm-
derived glia (Akiyama et al., 1996; Hosoya et al., 1995; Jones
et al., 1995; Schreiber et al., 1997; Vincent et al., 1996). gcm
loss-of-function mutant embryos lack nearly all lateral glial
cells, and presumptive glial cells are transformed into
neurons (Hosoya et al., 1995; Jones et al., 1995; Vincent et
al., 1996). Conversely, when gcm is ectopically expressed,
presumptive neurons are transformed into glia (Hosoya et
al., 1995; Jones et al., 1995). Thus, within the nervous
system, gcm acts as a genetic switch, with Gcm-positive
cells becoming glia and Gcm-negative cells becoming neu-
rons. Moreover, nonneural cells may adopt a glial cell fate
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All rights reserved.when forced to express gcm (Akiyama-Oda et al., 1998;
Bernardoni et al., 1998).
In addition to acting as a regulator of glial cell differen-
tiation, gcm has been found to have an instructive role in
the development of the plasmatocyte/macrophage lineage
of blood cells (Bernardoni et al., 1997; Lebestky et al., 2000).
Embryonic blood cells, or hemocytes, are derived from the
procephalic mesoderm (Tepass et al., 1994). Hemocyte
precursors give rise to two populations of hemocytes in the
embryo: plasmatocytes and crystal cells (Mathey-Prevot
and Perrimon, 1998). Plasmatocytes constitute the majority
of circulating hemocytes. They migrate throughout the
embryo in the hemolymph space, where they convert into
macrophages that are responsible for the phagocytosis of
apoptotic cells (Abrams et al., 1993; Tepass et al., 1994).
Early plasmatocytes, first seen in stage 10 embryos, ex-
press the extracellular matrix protein Peroxidasin. Peroxi-
dasin expression is maintained throughout embryogenesis
(Abrams et al., 1993; Nelson et al., 1994; Tepass et al.,
1994). In stage 11, plasmatocytes begin to express Croque-
mort, a CD36 related macrophage receptor (Franc et al.,8214. E-mail: bjones@saturn.med.nyu.edu.369
1996), and they convert into macrophages. Croquemort
expression is required for the efficient phagocytosis of
apoptotic cells (Franc et al., 1999). By the end of embryo-
genesis, nearly all plasmatocytes are macrophages that
express the Croquemort receptor.
Before gcm is activated in glial progenitors, gcm is ex-
pressed in the primordium of hemocyte precursors (Bernar-
doni et al., 1997; Jones et al., 1995). gcm continues expres-
sion in hemocyte precursors as they develop into
plasmatocytes through stage 11, after which it rapidly
disappears (Bernardoni et al., 1997). As plasmatocytes mi-
grate out of the procephalon and convert into macrophages,
gcm expression can no longer be detected.
gcm has been proposed to promote the differentiation of
plasmatocytes (Bernardoni et al., 1997; Lebestky et al.,
2000). Early misexpression of gcm induces an increase in
circulating plasmatocyte numbers in the embryo (Bernar-
doni et al., 1997). Ectopic expression of gcm in the crystal
cell lineage of hemocytes induces Croquemort expression
and the adoption of plasmatocyte characteristics (Lebestky
et al., 2000). gcm mutant embryos are deficient by 40% in
plasmatocyte numbers (Bernardoni et al., 1997). These
results indicate an instructive role for gcm in plasmatocyte/
macrophage development, and gcm has been proposed to be
a master regulator of the plasmatocyte/macrophage lineage
(Bernardoni et al., 1997). However, since mutation of gcm
causes only a decrease in plasmatocyte numbers (Bernar-
doni et al., 1997). without changing their ability to differ-
entiate into macrophages (Jones et al., 1995), gcm cannot be
the sole determinant of plasmatocyte/macrophage cell fate.
In this paper, we describe the characterization of a ho-
molog of the gcm gene in Drosophila, gcm2. gcm2 was
previously identified as a PCR fragment containing a gcm-
motif (Akiyama et al., 1996), the highly conserved DNA-
binding domain (Akiyama et al., 1996; Schreiber et al.,
1997) that is shared with gcm’s two mammalian homologs
(Akiyama et al., 1996; Altshuller et al., 1996; Kim et al.,
1998). We found gcm2 located 27.9 kb proximal to gcm, and
show that gcm2 has partially redundant functions with
gcm. gcm2 is expressed in a pattern similar to gcm, but at
lower levels, in glial cells and in hemocyte precursors.
Ectopic expression of gcm2 is sufficient to induce glial cell
differentiation. Moreover, a deletion of both genes com-
pletely removes all glial cell development, apart from the
midline glia. While this paper was in preparation, similar
results were reported (Kammerer et al., 2001); however,
without a mutation in gcm2, its exact role in development
was not clear. Here, we describe a null mutation of gcm2
and its effects on both glial cell and hemocyte differentia-
tion.
gcm2 loss-of-function has only a mild effect on glial cell
differentiation. More significant is its role in plasmatocyte/
macrophage differentiation. Like the gcm mutation, gcm2
loss-of-function results in a deficit in plasmatocytes. Dele-
tion of both gcm and gcm2 results in the striking absence of
Croquemort expression. However, Peroxidasin-expressing
hemocytes are still present. These Peroxidasin-expressing
hemocytes are reduced in numbers by over half, fail to
undergo normal migration, and do not exhibit the morphol-
ogy associated with their complete conversion into macro-
phages. We conclude that gcm and gcm2 are not required for
the initial specification of the plasmatocyte lineage but are
necessary for the proliferation of plasmatocyte precursors,
the expression of Croquemort protein, and the ability of
plasmatocytes to convert into macrophages.
MATERIALS AND METHODS
Identification and Analysis of gcm2 Locus and
cDNA
Database searches for gcm homologs using the BLAST program
(Altschul et al., 1997) identified an open reading frame (ORF) with
homology to gcm located on a Drosophila melanogaster genomic
library clone BACR24A22 (GenBank Accession No. AC007257),
which had been generated and sequenced by the Berkeley Drosoph-
ila Genome Project (BDGP). A pair of oligonucleotide primers
flanking the ORF (forward, AGTACGCATTCGGTGCATCC; and
reverse, ACTGTGTTGTTGCTGTCGTC) was used to amplify a
0.7-kb PCR product from the BACR24A22 DNA template. This
PCR product was used to screen a 9- to 12-h D. melanogaster
embryonic cDNA library (Zinn et al., 1988). A single gcm2 cDNA
was isolated; the 3-kb insert was subcloned into pBluescript SK()
(Stratagene) and sequenced (GenBank Accession No. AF461416).
In Situ Transcript Localization
In situ hybridization in whole-mount embryos was performed by
using digoxigenin-labeled riboprobes as described previously (Jones
et al., 1995). gcm antisense probes were generated from a full-
length gcm cDNA (Jones et al., 1995). thioredoxin probe was
generated from a thioredoxin cDNA, GH24203, identified by the
BDGP (Rubin et al., 2000), and obtained from ResGen.
Immunohistochemistry
Horseradish peroxidase (HRP) immunohistochemistry and em-
bryo dissection were done as previously described (Patel, 1994).
Anti-Repo monoclonal antibody (MAb) (MAb 8D12; B.W.J., B.
Blankemeier, and C. S. Goodman, unpublished observations) was
used at a 1:5 dilution. Rabbit anti-Croquemort antibody (Ab) (Franc
et al., 1996) was used at a 1:1000 dilution, mouse anti-Peroxidasin
Ab (Nelson et al., 1994) at 1:500, mouse anti--galactosidase (-gal)
MAb (Roche) at 1:500, and rabbit anti--gal Ab (Cappel) at 1:10,000.
Secondary antibodies conjugated to HRP or Biotin (Jackson Immu-
noResearch) were used at 1:300 dilutions. Biotinylated secondary
antibodies were detected by using Vectastain Elite ABC and HRP/
diaminobenzidine (DAB) reaction. DAB reactions were enhanced to
give a black color by addition of 0.067% NiCl2.
D. melanogaster Stocks and Genetics
Wild-type embryos were w1118. The gcm null allele gcmPI
(FBa10045751) and UAS-gcm reporter lines P{UAS-gcm.J}2 and
P{UAS-gcm.J}3 (FBal0045765) were described previously (Jones et
al., 1995) Df(2L)200 (FBab0022176) was described by Lane and
Kalderon (1993). Df(2L)200 and gcmPI were balanced over CyO,
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P{wmC Act5C-lacZ} (FBba0000031) for the identification of mutant
embryos.
USA-gcm2 lines were generated by inserting the gcm2 cDNA
into pUAST, a UAS reporter P element vector (Brand and Perrimon,
1993), to generate P{UAS-gcm2}. Several lines carrying P {UAS-
gcm2} insertions were generated by using P element-mediated
transformation into w1118 flies using standard methods.
Ectopic expression of gcm2 or gcm in neuroblasts was achieved
by crossing P{UAS-gcm2} or P{UAS-gcm.J} with sca-Gal4
(FBa10040466) (Klaes et al., 1994). Ectopic expression of gcm in a
Df(2L)200 background was achieved by using daughterless-Gal4
(da-Gal4) (FBti0013991) (Wodarz et al., 1995), by crossing
Df(2L)200/CyO;P{UAS-gcm.J}3 with Df(2L)200/CyO;da-Gal4. Ex-
pression of a lz reporter gene (lz-lacZ) in a Df(2L)200 background
was achieved by crossing lz-Gal4;Df(2L)200/ males with
Df(2L)200/;UAS-lacZ/ females. lz-Gal4 (FBti0003702) and
UAS-lacZ (FBti0002140) have been described previously (Brand and
Perrimon, 1993; Crew et al., 1997; Lebestky et al., 2000).
Deletions at the gcm2 locus were generated by imprecise exci-
sion of a P element as previously described (Jones et al., 1995),
using the P element P(EP)2018 (FBti0010775) (Liao et al., 2000;
Rorth et al., 1998). Several hundred w lines were generated and
analyzed by Southern blot to detect deletions; one of these excision
lines, Df(2L)gcm2, has a deletion that removes the entire ORF of
gcm2 as well as the thioredoxin promoter (see Fig. 5).
Molecular Characterization of Df(2L)200 and
Df(2L)gcm2
The deletion breakpoints of Df(2L)200 and Df(2L)gcm2 were
determined by Southern analysis using probes generated from
genomic DNA walks of the region spanning 30B–30C (Jones et al.,
1995; Lane and Kalderon, 1993), as well as probes generated from
the gcm2 and thioredoxin cDNAs. The extent of the Df(2L)gcm2
deletion was determined by amplifying a 0.9-kb PCR product using
primers flanking the deletion (forward, CGAAGTGAGACGC-
TATCAGC; and reverse, CCTGGTACACCATGTTGGAT), with
genomic DNA from homozygous Df(2L)gcm2 flies as a template.
The PCR product, cloned into pCR2.1 (Invitrogen), was sequenced.
RESULTS
Identification and Characterization of the gcm2
Locus
A second gcm-motif gene in D. melanogaster, named
gcm2, was originally identified from a 137-bp PCR product
amplified from D. melanogaster genomic DNA using de-
generate primers (Akiyama et al., 1996). Using BLAST
searches (Altschul et al., 1997), we found a sequence with
significant homology to gcm on a D. melanogaster genomic
library clone. This sequence has an ORF with a gcm-motif
and identity to the predicted sequence of the gcm2 PCR
fragment. BLAST searches with the near complete sequence
of the D. melanogaster genome (Adams et al., 2000) failed
to identify additional gcm-motif genes. We concluded that
we had identified gcm2.
A 0.7-kb PCR product was amplified by using primers
flanking the gcm2 ORF. This PCR product was used as a
probe to isolate a single 3-kb clone from an embryonic
cDNA library. The cDNA clone was sequenced. It has an
ORF that encodes a protein of 613 amino acids (Fig. 1B), a
928-bp 5 UTR, and a 171-bp 3 UTR with poly(A) tail.
Comparison with the published genomic sequence (Gen-
Bank Accession No. AE003625; Adams et al., 2000) re-
vealed the gcm2 transcription unit to have 3 exons and a
location 27.9 kb 5 to the gcm gene, in opposing orienta-
tion (Fig. 1A). Located between gcm2 and gcm are two
predicted genes encoding for carboxylesterases (CG3841
and CG4382). Immediately 3 of gcm2 is the thioredoxin
gene, one of several Thioredoxin-like genes in Drosophila.
The predicted amino acid sequence and exon structure of
gcm2 are in agreement with the prediction of the Genome
Project (GenBank Accession No. AAF52793), differing in
amino acid sequence at only six residues (bold, underlined
in Fig. 1B). However, our cDNA differs from that of Kam-
merer et al. (2001) at the 5 end. Their cDNA (GenBank
Accession No. AF184664) has a fourth, alternative 5 exon,
located upstream, that replaces the first 11 residues of our
predicted protein with four different residues. These results
suggest that gcm2 has two separate promoters with alter-
nate splicing at the 5 end.
Gcm2 protein is similar in structure to other Gcm family
members, sharing a highly conserved N-terminal gcm-motif
of 156 amino acids (boxed in black in Fig. 1B). While all
Gcm family members are very similar in the gcm-motif,
Gcm2 and Gcm are more similar to each other (69%
identity; 83% similarity) than to their two vertebrate coun-
terparts Gcm1/GCMa and Gcm2/GCMb (55–64% identity;
70–78% similarity to human Gcm1 and Gcm2) (Fig. 1C).
Expression of gcm2 Transcripts
We followed gcm2 expression in embryos using in situ
hybridization to mRNA. Similar results were obtained
whether we used a full-length probe for gcm2 or a probe
made from the first 930 bp of the gcm2 cDNA that en-
sured no cross-hybridization with gcm mRNA. Cross-
hybridization with gcm was of concern as the expression
profiles of the two genes overlap, though gcm2 is expressed
at much lower levels. With gcm2 and gcm probes of similar
lengths under identical hybridization conditions, gcm2
transcripts were first detected after 3 h of reaction, while
gcm transcripts were detected after only 5 min of reaction.
The expression profiles of gcm2 transcripts compared
with gcm are shown in Fig. 2. Like gcm, gcm2 is first
detected in an anterior ventral region in stage 5 embryos
(Fig. 2A). During gastrulation, these cells invaginate at the
end of the ventral furrow just anterior to the cephalic
furrow, in the primordium of presumptive hemocyte pre-
cursors (Fig. 2C). Expression in hemocyte precursors per-
sists through stage 11, after which it rapidly fades. At late
stage 9, gcm2 is first detected in the neuroectoderm in each
hemisegment in a single cell at the lateral edge of the CNS
(Fig. 2E). At stage 11, gcm2 continues to be expressed in a
single cell per CNS hemisegment, which is now in the
position of neuroblast NB1-3 or its progeny (Fig. 2G). NB1-3
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gives rise to several CNS and peripheral glial (Schmidt et
al., 1997). By stage 12, gcm2 is detected in longitudinal glia
precursors, as well as other CNS glia, and in a stripe of
ectodermal cells of the lateral body wall in each hemiseg-
ment (Fig. 2I). Through stage 15, gcm2 continues to be
detected in the longitudinal glia, in other CNS glia at very
low levels, and in the lateral ectoderm (Figs. 2K and 2M).
After stage 15, gcm2 expression rapidly fades.
In summary, the expression pattern of gcm2 in part
mirrors that of gcm, but expression is at very low levels
compared with that of gcm. gcm2 expression is highest in
the hemocyte primordia and in the longitudinal and nerve
root glia.
Ectopic Expression of gcm2 Induces Glial Cell
Differentiation
The similarity between Gcm2 and Gcm proteins, espe-
cially in the gcm-motif, suggested they have redundant
functions. Ectopic expression of gcm is sufficient to pro-
mote glial cell differentiation, transforming presumptive
neurons into glia (Hosoya et al., 1995; Jones et al., 1995). To
test whether ectopic expression of gcm2 is sufficient to
promote glial cell differentiation, we used the Gal4/UAS
binary system (Brand and Perrimon, 1993) to generate
embryos that express gcm2 in all presumptive neuroblasts.
UAS-gcm2 flies were crossed with sca-Gal4 (Klaes et al.,
1994), which drives expression throughout the neurogenic
ectoderm and developing neuroblasts. In sca-Gal4;UAS-
gcm2 embryos, there is a striking increase in the number of
glial cells as revealed by anti-Repo antibody (Fig. 3C), a
glial-specific marker (Campbell et al., 1994; Halter et al.,
1995; Xiong et al., 1994). Many of these Repo-positive cells
exhibit the elongated or irregular cell shapes typical of glial
cells. This phenotype is similar to that of ectopically
expressed gcm (Fig. 3B). Similar results were also shown by
Kammerer et al. (2001); in addition, they induced ectopic
gcm2 in neuroblasts in gcm null mutant embryos and
demonstrated that gcm2 is sufficient, in the absence of gcm,
to induce gliogenesis.
gcm2 Is Necessary for Gliogenesis
gcm mutant embryos retain a low level of glial cell
development (Hosoya et al., 1995; Jones et al., 1995; Vin-
cent et al., 1996). gcmPI is a null allele that deletes the
transcription unit. In gcmPI mutant embryos, isolated
single Repo-positive cells, as well as occasional small
clusters of Repo-positive cells can be seen in many seg-
ments (Fig. 4C). These glial cells are typically, but not
always, in the positions longitudinal glia and nerve root
glia—cells in which gcm2 expression is strongest. The
number of Repo-positive cells per hemisegment may vary
from 0 to as many as 8. We counted an average of 2
Repo-positive cells per hemisegment in the ventral nerve
cord (n  180 hemisegments) (Fig. 4C), compared with the
wild-type number of 30 glial cells per hemisegment (Fig.
4B). To ask whether gcm2 is required for the glial cell
development in gcm mutants, we analyzed homozygous
Df(2L)200 embryos. Southern blot analysis established that
Df(2L)200 is a deletion removing approximately 120 kb that
includes both gcm and gcm2, as well as 15 other predicted
genes, none of which are known to affect glial cell differen-
tiation (Fig. 4A). In Df(2L)200 homozygous embryos, Repo
staining is completely abolished (Fig. 4D). These results
implicate gcm2 in promoting glial cell differentiation.
To gain further evidence for a role for gcm2 in gliogenesis,
we isolated a deletion allele of gcm2. A P element inserted
into the 5 UTR of the thioredoxin gene, located 584 bp 3
of the gcm2 polyadenylation site, was mobilized to recover
small deletions at the gcm2 locus. We recovered one dele-
tion, Df(2L)gcm2, that removes the entire gcm2 ORF as
well as the thioredoxin promoter (Fig. 5A). This mutation is
homozygous viable. Homozygous Df(2L)gcm2 embryos
lack gcm2 expression (data not shown). Df(2L)gcm2 em-
bryos also show altered thioredoxin expression. thioredoxin
transcripts are normally expressed at high levels in the gut
and at low levels throughout the embryo (data not shown).
In Df(2L)gcm2 embryos, the normal pattern of thioredoxin
expression is abolished. But a low level of thioredoxin
expression is detected in the pattern of gcm2, reflecting a
fusion of thioredoxin with the gcm2 promoter (data not
shown). Smaller deletions removing just the thioredoxin
promoter are homozygous viable but sterile, suggesting that
the low level of thioredoxin expressed in Df(2L)gcm2 res-
cues the sterility of thioredoxin mutation.
The pattern of Repo expression in Df(2L)gcm2 homozy-
gous embryos is normal (Fig. 5B), demonstrating that gcm2
alone is not necessary for gliogenesis. However gcm2’s role
in gliogenesis is revealed in a background where gcm
expression is reduced by half. When Df(2L)gcm2 is crossed
with Df(2L)200 embryos, removing one copy of gcm and
two copies of gcm2, the resulting transheterozygotes are
lethal, and glial cell deficiencies are consistently observed.
Glial cell deficiencies are most notable in the longitudinal
glia tracts, but are also observed with other CNS glial cell
types (Figs. 5C–5E). To assay the penetrance of this glial
cells missing phenotype, we counted longitudinal glia (LG)
in Df(2L)gcm2/Df(2L)200 embryos. In wild-type and in
Df(2L)gcm2 homozygous embryos, we counted an average
of 8.5 LG per hemisegment (n  656 767, respectively). In
Df(2L)gcm2/Df(2L)200 embryos, we counted an average of
6.4 LG per hemisegment (n  1106). Thus, lowering the
dosage of gcm and completely removing gcm2 reveals the
contribution of gcm2 to glial cell differentiation, especially
in the LG lineage.
Both gcm2 and gcm Are Required Together for the
Terminal Differentiation of Plasmatocytes
Both gcm and gcm2 are expressed in the primordia of
embryonic hemocytes and in plasmatocytes through stage
11. In gcm mutant embryos, there is a decrease by 40% in
the number of plasmatocytes (Bernardoni et al., 1997).
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FIG. 1. Map of the gcm/gcm2 locus, Gcm2 sequence, and comparison to human homologs. (A) Map of genomic region 30B–30C, showing
locations of gcm2, gcm, and three other predicted genes, derived from sequences and gene predictions from the Drosophila Genome Project
(GenBank Accession No. AE003625; Adams et al., 2000) and from experimental data. Arrows indicate direction of transcription. Predicted
transcript structures are shown below the line, with rectangles representing exons; black regions within the rectangles represent predicted
ORFs. Distal to proximal orientation is from left to right. (B) Predicted amino acid sequence of Gcm2 protein. Gcm-motif is boxed in black.
The six amino acid residues that differ from the predicted sequence of the Genome Project are underlined in bold. (C) Sequence alignments
of gcm-motifs of D. melanogaster Gcm2, D. melanogaster Gcm (GenBank Accession No. AAC46912), H. sapiens hGcm1 (GenBank
Accession No. BAA13651), and H. sapiens hGcm2 (GenBank Accession No. AAC33792). Sequence identities are boxed in black. Conserved
cysteine and histidine residues are marked underneath. The percentage sequence identity is shown in the lower half, and the percentage
sequence similarity is shown in the upper half of the inserted table. Sequence similarities are based on BLAST analysis. Note that Gcm2
and Gcm are more similar to each other than to their human homologs.
FIG. 2. In situ localization of gcm2 and gcm transcripts in whole-mount embryos at different stages, viewed ventrally, with anterior to
the left. gcm2 expression (A, C, E, G, I, K, M) is shown after 6 h of staining reaction. gcm expression (B, D, F, H, J, L, N) is shown after 1 h
of staining reaction. (A, B) Stage 5: gcm2 (A) and gcm (B) are expressed in a ventral anterior patch of cells in presumptive procephalic
mesoderm (arrowheads). (C, D) Stage 6: gcm2 (C)-and gcm (D)-expressing cells invaginate into the ventral furrow anterior to the cephalic
furrow (arrowheads). (E, F) Stage 9: gcm2 (E) is expressed in procephalic mesoderm (arrowhead) and in a single cell per hemisegment at the
lateral edge of the neuroectoderm (arrow); gcm (F) is expressed in a patch of cells at the same position as gcm2 at the lateral edge of the
neuroectoderm (arrow), as well as in procephalic mesoderm (arrowhead). (G, H) Stage 11: gcm2 (G) continues to be expressed in a single cell
per CNS hemisegment (arrow) and in hemocyte precursors (arrowhead); gcm (H) is expressed in the same cell as gcm2 in the CNS (arrow)
as well as other glial precursors and in hemocyte precursors (arrowhead). (I, J) Stage 12: gcm2 (I) is expressed in migrating longitudinal glia
(arrow) at low levels in other CNS glia; gcm (J) is expressed at high levels in all developing glia, including the longitudinal glia (arrow). Both
gcm2 and gcm begin expression in a stripe of lateral ectodermal cells (thin arrows). Note that gcm2 and gcm are no longer expressed in
hemocytes at stage 12. (K, L) Stage 13: gcm2 (K) is detected in longitudinal glia (arrow), as well as in other glia; gcm (L) is expressed in all
glia. (M, N) Stage 15: gcm2 and gcm expression fades in the ventral nerve cord. Scale bar, 50 m.
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Given that gcm2 may have redundant functions with gcm
in the plasmatocyte lineage, we counted Croquemort-
positive cells in Df(2L)gcm2 embryos. At stage 15, we found
an average of 219 per half embryo in Df(2L)gcm2 mutants
(n  6; 226, 202, 223, 196, 210, 259), as compared with
294 per half embryo in wild type (n  6; 303, 314, 292,
FIG. 3. Ectopic expression of gcm2 promotes glial cell differentiation. (A–C) Dissected stage 16 embryos showing five adjacent segments of the
CNS labeled with Repo monoclonal antibody. (A) Wild-type. (B) sca-Gal4;UAS-gcm. (C) sca-Gal4;UAS-gcm2. Panneural expression of gcm (B) or
gcm2 (C) induces a significant increase in CNS cells expressing Repo protein that adopt glial cell morphologies. Anterior is up. Scale bar, 10 m.
FIG. 4. A deletion removing both gcm and gcm2 results in loss of all lateral glial cells. (A) Map of 30B–30C region of chromosome 2
showing the 120 kb of DNA removed by the Df(2L)200 deletion. Red line shows extent of deletion, with the dashed part showing
uncertainty. Predicted genes are represented with arrows, with names shown underneath. Solid black line represents scale in DNA base
pairs. (B–D) Dissected stage 16 embryos showing five adjacent segments of the CNS labeled with Repo monoclonal antibody with the
following genotypes: (B) wild-type, (C) gcmPI, and (D) Df(2L)200. In the gcm null mutant embryo (C), there remains a low level of glial cell
development in the CNS as shown by Repo expression. Df(2L)200 mutant embryo (D), deleting both gcm and gcm2, completely lacks Repo
expression. Anterior is up. Scale bar, 10 m.
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283, 310). This constitutes a 25% reduction in the number
of Croquemort-positive hemocytes in Df(2L)gcm2 embryos
compared with wild-type. We also looked at Peroxidasin
protein expression, which is an early marker of the plas-
matocyte lineage (Abrams et al., 1993; Nelson et al., 1994;
Tepass et al., 1994). At stage 15, we counted an average of
234 Peroxidasin-labeled hemocytes per half embryo in
Df(2L)gcm2 mutants (n  6; 205, 240, 248, 204, 257,
251), as compared with 314 per half embryo in wild type
(n  6; 306, 341, 297, 314, 322, 301). This constitutes
a 26% reduction in Peroxidasin-labeled hemocytes in
Df(2L)gcm2 embryos compared with wild type.
In Df(2L)200 mutant embryos, deleting both gcm and
gcm2, we found a complete absence of Croquemort expres-
sion (Fig. 6B). To ascertain the fate of hemocytes in
Df(2L)200 embryos, we also looked at Peroxidasin expres-
sion. In Df(2L)200 embryos, Peroxidasin-labeled hemocytes
are still present (Fig. 7); however, they are reduced in
number and have aberrant morphologies and migration
behavior. In wild-type stage 13 embryos, plasmatocytes
migrate from the head along different routes: midventrally
between the ventral epidermis and ventral nerve cord (Fig.
7C), between the dorsal surface of the nerve cord and the
mesoderm, along the dorsal boundary of the epidermal
FIG. 5. Mutation of gcm2 effects glial cell differentiation. (A) Map of gcm2 deletion. Upper part, Wild-type exon structure of gcm2 and
thioredoxin are shown as rectangles, with black regions denoting predicted ORFs. Arrows below, at start of genes, denote the beginning of
the gcm2 cDNA (1), and the start site of thioredoxin based on the longest ESTs from BDGP (Rubin et al., 2000). P element P(EP)2018 is
inserted in the 5UTR of thioredoxin and is located 584 bp downstream of the gcm2 polyadenylation site. Lower part, Map of deletion
Df(2L)gcm2 induced by imprecise excision of P(EP)2018. The deletion starts at position 736 and ends at position 3629 relative to the
5 end of the gcm2 cDNA. Sequence analysis revealed a deletion of 2894 bp, replaced with nine unrelated nucleotides. This deletion
removes the entire gcm2 ORF as well as the 5 end of the thioredoxin gene. (B–E) Dissected stage 16 embryos showing five adjacent
segments of the CNS labeled with Repo monoclonal antibody. (B) Df(2L)gcm2 homoygous embryo. Deletion of gcm2 is viable and has
normal pattern of Repo expression. (C–E) Df(2L)gcm2/Df(2L)200 embryos. A twofold reduction of gcm and the complete removal of gcm2
result in glial cell deficiencies. Missing longitudinal glia are denoted by arrows. Anterior is up. Scale bar, 10 m.
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primordium (Fig. 7A), and along the gut primordium. In
Df(2L)200 stage 13 embryos, most Peroxidasin-labeled he-
mocytes remain in the cephalic region. They fail to migrate
ventrally past the 2nd thoracic segment (Fig. 7D), and those
that migrate dorsally stay clumped together along the
dorsal boundary of the epidermis (Fig. 7B). By stage 15,
wild-type plasmatocytes are distributed throughout the
embryo, with many found on the ventral surface of the CNS
(Figs. 7E and 7G). In Df(2L)200 stage 15 embryos, a reduced
number of Peroxidasin-labeled hemocytes is evident; most
of them are in cephalic and dorsal positions, as well as
around the gut (Fig. 7F). Very few hemocytes are found
along the ventral surface of the CNS (Fig. 7H). At stage 15,
we counted an average of 127 Peroxidasin-labeled hemo-
cytes per half embryo in Df(2L)200 mutants (n  6; 132,
119, 151, 133, 121, 110), as compared with 314 per half
embryo in wild type. This constitutes a 60% reduction in
the number of Peroxidasin-labeled hemocytes in Df(2L)200
embryos compared with wild type.
By stage 16, 90% of Peroxidasin-labeled hemocytes in
wild-type embryos have converted into macrophages that
are enlarged due to phagocytic activity (Tepass et al., 1994).
Macrophages are typically 8–15 microns in diameter and
contain large vacuoles filled with dark inclusions (Figs. 8A
and 8C). In Df(2L)200 embryos, the majority of Peroxidasin-
labeled hemocytes are small, rounded, but irregular in
shape, and less than 5 microns in diameter; some contain
small vacuoles and occasionally enlarge up to 8 microns
(Figs. 8B and 8D).
Given these phenotypes, we were curious to test whether
expression of gcm in gcm/gcm2-deficient embryos was
sufficient to rescue Croquemort expression in hemocytes.
We used daughterless-Gal4 (da-Gal4) (Wodarz et al., 1995)
to drive ubiquitous expression of UAS-gcm throughout
embryogenesis in Df(2L)200 embryos. In Df(2L)200;UAS-
gcm/da-Gal4 embryos, there is a partial rescue of Croque-
mort expression in hemocytes (Fig. 6C). We counted an
average of 68 Croquemort-positive hemocytes per half
stage 15 embryo (n  6; 54, 63, 57, 76, 85, 72), which is
23% of the normal complement of Croquemort-positive
hemocytes. These Croquemort-positive hemocytes are dis-
tributed throughout the embryo and have the enlarged
characteristics of wild-type macrophages. These results
demonstrate that expression of gcm alone is sufficient to
rescue both Croquemort expression and the migration and
morphological defects associated with hemocytes that lack
endogenous gcm and gcm2 genes.
Hemocyte precursors generate two populations of embry-
onic hemocytes: plasmatocytes (approximately 600–700)
that migrate throughout the embryo, and crystal cells
(approximately 40–60) that are clustered around the pro-
ventriculus (Lebestky et al., 2000; Mathey-Prevot and Perri-
mon, 1998; Tepass et al., 1994). Crystal cell differentiation
is promoted by the lozenge (lz) gene, and gcm expression is
excluded from the crystal cell population (Lebestky et al.,
2000). lz expression was found not to be altered in gcm
mutants (Lebestky et al., 2000). To test whether the num-
ber of crystal cells is altered in gcm/gcm2-deficient em-
bryos, we looked at lz expression as monitored by a UAS
lacZ reporter driven by a lz-Gal4 driver (lz-lacZ) in
Df(2L)200 embryos. We detected no change in the number
or position of lz-lacZ-expressing cells (data not shown).
These results exclude the possibility that some presump-
tive plasmatocytes had been transformed into crystal cells
in embryos that lack both gcm and gcm2.
DISCUSSION
gcm2 Functions Overlap with gcm in Both Glial
Cell and Hemocyte Development
gcm has previously been shown to be the primary regu-
lator of lateral glial cell fate in Drosophila. In addition, gcm
has been implicated in promoting the differentiation of the
plasmatocyte/macrophage lineage of blood cells. In this
paper, we describe a second gcm-like gene, gcm2, which has
FIG. 6. gcm/gcm2-deficient embryos lack Croquemort expres-
sion. Ubiquitous expression of gcm in gcm/gcm2-deficient embryos
rescues Croquemort expression in hemocytes. (A–C) Whole-mount
stage 16 embryos (lateral view, anterior to left) stained with anti-
Croquemort antibody. (A) Wild-type. (B) Df(2L)200. (C) Df(2L)200;
UAS-gcm/da-Gal4. Df(2L)200 mutant embryos (B), deficient for both
gcm2 and gcm, completely lack Croquemort expression in hemo-
cytes. Ubiquitous expression of gcm in Df(2L)200 embryos (C) re-
stores Croquemort expression in hemocytes. Scale bar, 50 m.
377gcm2 and gcm Promote Macrophage Development
© 2002 Elsevier Science (USA). All rights reserved.
functions that overlap those of gcm. We have shown that
gcm2 has a minor role in gliogenesis, and a more significant
role in hemocyte differentiation. Analysis of a deletion of
both genes has allowed us to clarify the role of these two
transcription factors in plasmatocyte development. We
present evidence that gcm and gcm2 are required for the
proliferation and maturation of plasmatocytes, but not their
initial specification.
The sequence of Gcm2 protein is closely related to Gcm,
especially in the highly conserved gcm-motif DNA-binding
domain, where it shares 69% identity. While the degree of
similarity between the gcm-motifs of all Gcm family
members is close. D. melanogaster Gcm2 and Gcm are
more similar to each other than to their two mammalian
counterparts Gcm1/GCMa and Gcm2/GCMb, suggesting
that independent duplications produced these two gene
FIG. 7. gcm/gcm2-deficient embryos show aberrant plasmatocyte differentiation. (A–H) Whole-mount embryos at different stages stained
with anti-Peroxidasin antibody (anterior to left). (A, C) Wild-type stage 13. Lateral view (A) shows plasmatocytes located in the head and
migrating dorsally along the edge of the epidermis and ventrally along the developing CNS. Ventral view (C) shows plasmatocytes migrating
along the ventral surface of the CNS (arrows). (B, D) Df(2L)200, gcm/gcm2-deficient embryos, stage 13. Lateral view (B) shows fewer
plasmatocytes, most located in the head; some have migrated out of the head, but are clustered at the dorsal edge of the epidermis (arrow).
Ventral view (D) shows that plasmatocytes do not migrate along the ventral surface of the CNS past the second thoracic segment (arrow).
(E, G) Wild-type stage 15. Lateral view (E) shows plasmatocytes distributed throughout the hemolymph. Ventral view (G) shows
plasmatocytes distributed around the ventral surface of the CNS. (F, H) Df(2L)200, gcm/gcm2-deficient embryos, stage 15. Lateral view (F)
shows fewer plasmatocytes; most are still located in the head, though some plasmatocytes are scattered in the hemolymph of the dorsal
half of the embryo. Ventral view (H) shows very few plasmatocytes on the ventral surface of the CNS. Scale bar, 50 m.
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pairs. Gcm and its mammalian homologs have all been
shown to bind the same octamer-binding site sequence
with similar affinities (Akiyama et al., 1996; Schreiber et
al., 1997, 1998; Tuerk et al., 2000). Expression of rat or
mouse Gcm1/GCMa in Drosophila is sufficient to activate
glial cell development (Kim et al., 1998; Reifegerste et al.,
1999). Given these results, it is likely that D. melanogaster
Gcm2 has similar DNA-binding and functional specifici-
ties. gcm2’s location, only 27.9 kb from gcm, and their
similar expression patterns suggest the possibility that gcm
and gcm2 share regulatory regions (Kammerer et al., 2001).
gcm2 Promotes Gliogenesis
The presence of a second factor promoting gliogenesis
explains why a small number of glial cells still develop in
gcm null mutants. gcm2 is expressed at very low levels in
lateral glial cells. The complete deletion of both gcm and
gcm2 results in the elimination of all lateral glial cell
development. Ectopic expression of gcm2 induces gliogen-
esis, and its effectiveness is indistinguishable from gcm
(Fig. 3). These results suggest that Gcm and Gcm2 proteins
have redundant biochemical capabilities, which are likely
to be mediated through the similar gcm-motif DNA-
binding domains.
Mutation of gcm2 alone is viable and has little effect on
glial cell differentiation, confirming that the presence of
normal gcm expression is sufficient to carry out gliogenesis
in the absence of gcm2. However, when gcm2 mutation is
crossed with a deletion removing both gcm and gcm2, the
resulting transheterozygote is lethal, and glial cell deficien-
cies are visible. Thus, a twofold reduction of gcm and the
complete removal of gcm2 reveal a small contribution of
gcm2 to glial cell differentiation, especially in the LG
lineage, where gcm2 expression is highest. This phenotype
shows that glial cell differentiation is sensitive to the
dosage of gcm and gcm2 gene products. Kammerer et al.
(2001) demonstrated that in gcm mutant embryos there is a
FIG. 8. In gcm/gcm2-deficient embryos, plasmatocytes do not convert into normal macrophages. (A–D) Magnified views of anti-
Peroxidasin-labeled plasmatocytes at stage 16. (A, C) Wild-type viewed from the dorsal surface (A) and on the ventral anterior surface of the
CNS (C). Nearly all wild-type plasmatocytes have become enlarged macrophages that are typically 8–15 microns in diameter and contain
large vacuoles filled with dark inclusions (arrows). (B, D) Df(2L)200, gcm/gcm2-deficient embryos viewed from the dorsal surface (B) and
on the ventral anterior surface of the CNS (C). In Df(2L)200, gcm/gcm2-deficient embryos, most Peroxidasin-labeled hemocytes remain
small and irregular in shape (arrow heads). An occasional Peroxidasin-labeled hemocyte may contain vacuoles and enlarge up to 8 microns
in diameter. (D, arrow). Scale bar, 20 m.
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reduction in the glial expression of gcm2 transcripts; in
addition, they showed that ectopic gcm expression induces
gcm2 expression, and vice versa. These results suggest that
cross-regulation between the two genes may contribute to
the phenotypes observed.
Dosage sensitivity and the regulation of gcm2 by gcm
may explain why gcm2 has a weak effect on glial cell
differentiation in gcm mutants. gcm2 is expressed at such
low levels that Gcm2 protein may be at concentrations
below a threshold that triggers glial cell differentiation.
Sporadically it surpasses this threshold in some neural
progenitors, triggering occasional longitudinal glia and
nerve root glia differentiation in the absence of gcm. It has
been proposed that a fairly high threshold for Gcm protein
is required to trigger glial cell differentiation in neuroglio-
blasts that give rise to both neurons and glia. In these
neuroglioblasts, low levels of Gcm expression are not
sufficient to trigger glial cell fate, but may be necessary to
confer glial potential when upregulated in daughter cells
(Freeman and Doe, 2001).
gcm and gcm2 Are Required for the Proliferation
of Plasmatocyte Precursors but Not Their Initial
Specification
It is clear that both gcm and gcm2 are required for the
proper differentiation of the plasmatocyte lineage. Muta-
tion of either gcm or gcm2 results in deficits in plasmato-
cyte numbers (Bernardoni et al., 1997; this study), and the
ectopic expression of gcm leads to extra plasmatocytes
(Bernardoni et al., 1997). Previous reports had suggested
that gcm specifies the plasmatocyte lineage, and that per-
haps the existence of a second gcm-motif gene in Drosoph-
ila accounted for the presence of only reduced number of
plasmatocytes in gcm mutants rather than their elimina-
tion (Bernardoni et al., 1997).
In light of this, we were surprised to find, in embryos
deficient for both gcm and gcm2, plasmatocyte-like cells
still developing and expressing the early plasmatocyte
marker Peroxidasin. However the number of Peroxidasin-
labeled hemocytes in gcm/gcm2-deficient embryos is re-
duced by 60% compared with wild type. This reduction
roughly corresponds to the combined reduction in plas-
matocytes in gcm and gcm2 mutant embryos together (40%
for gcm mutants plus 25% for gcm2 mutants). It has
previously been observed that the procephalic mesoderm,
from which plasmatocytes develop, forms a mitotic domain
that undergoes four divisions during embryonic stages 8–11
(Tepass et al., 1994). After the final division, most proce-
phalic mesoderm cells are recognizable as plasmatocytes
and undergo no further divisions (Tepass et al., 1994). These
cell divisions are coincident with the highest levels of gcm
and gcm2 expression. These results suggest that gcm and
gcm2 promote the proliferation of plasmatocyte precursors,
rather than their initial specification.
We believe that the increased number of plasmatocytes
observed when embryos receive an overexpression of gcm
under control of the heat shock promoter (Bernardoni et al.,
1997) is due to an over-proliferation of plasmatocytes in
the procephalic mesoderm, which subsequently migrate
throughout the embryo. Bernardoni et al. (1997) observed
that ectopic expression of gcm in the nervous system leads
to an increase in Peroxidasin-labeled hemocytes clustered
around the CNS. They ascribed this phenotype to a trans-
formation of CNS to hemocyte cell fate. We counted the
number of Peroxidasin-labeled hemocytes in sca-Gal4;
UAS-gcm embryos, where gcm is ectopically expressed in
all neuroblasts, and found that the number of plasmato-
cytes in stage 15 embryos is not significantly increased
(average of 320 Peroxidasin-labeled hemocytes per half
embryo; n  6; 292, 339, 287, 309, 358, 337), even
though their distribution has changed, with more macro-
phages observed around the CNS (data not shown). We
believe this phenotype arises from the recruitment of mac-
rophages to the CNS due to increased apoptosis, rather than
transformation of neurons into macrophages. Our results,
and those of others, show that ectopic expression of gcm
transforms presumptive neurons into glial cells (Hosoya et
al., 1995; Jones et al., 1995) but not into plasmatocytes,
consistent with combinatorial models of transcription fac-
tor action.
Hemocyte precursors in the embryo give rise to two
populations of blood cells, crystal cells and plasmatocytes
(Mathey-Prevot and Perrimon, 1998), promoted by the
GATA transcription factor Serpent (Rehorn et al., 1996).
Lack of Serpent results in the complete absence of hemo-
cytes (Rehorn et al., 1996). Crystal cells development is
promoted by the AML-1 transcription factor homolog Loz-
enge (Lebestky et al., 2000). In the absence of both gcm and
gcm2, the number and location of crystal cells remains the
same. We conclude that gcm and gcm2 do not act as ge-
netic switches between plasmatocyte and crystal cell fate.
However, ectopic expression of Gcm in the crystal cell
lineage causes them to express Croquemort and assume
plasmatocyte-like morphology (Lebestky et al., 2000) show-
ing that there is some plasticity between hemocyte lin-
eages.
The persistent expression of Serpent suggests that it may
continue to have a role in plasmatocyte development after
the initial specification of hemocyte precursors (Rehorn
et al., 1996). In addition, a second factor, U-shaped, is
expressed in plasmatocytes (Fossett et al., 2001). U-shaped
acts to limit the proliferation of crystal cells. In the absence
of U-shaped, there is an increase in the crystal cell popula-
tion, and forced expression of U-shaped reduces the crystal
cell population (Fossett et al., 2001). We suggest that a
combination of Serpent, U-shaped, lack of Lozenge expres-
sion, and perhaps unidentified factors promotes the initial
specification of plasmatocytes and Peroxidasin expression.
gcm and gcm2 Promote Macrophage Development
Our results are consistent with a requirement of gcm and
gcm2 for the conversion of plasmatocytes into macro-
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phages. Deletion of both gcm and gcm2 results in the
complete absence of Croquemort expression in hemocytes.
These mutant hemocytes retain Peroxidasin expression and
have some migratory properties characteristic of plasmato-
cytes; some move out of the procephalon and are ultimately
distributed in the hemolymph. However, many of these
mutant hemocytes remain in the head; those that do
migrate, migrate dorsally, and do not follow stereotypic
ventral paths along the surface of the CNS. Normal plas-
matocytes migrate to prominent sites of programmed cell
death (Abrams et al., 1993; Tepass et al., 1994). The
distribution of plasmatocytes in embryos lacking gcm and
gcm2 functions suggests that they are not attracted to cells
undergoing programmed cell death or that their ability to
migrate is impaired.
In addition, the majority of mutant plasmatocytes fail to
enlarge, nor do they contain large vacuoles filled with dark
inclusions. This phenotype suggests that most mutant
plasmatocytes lack phagocytic activity. We cannot rule out
that they are incabable of phagocytosis; the fact that a small
number of mutant plasmatocytes enlarge slightly may
indicate that they are competent for phagocytosis. Plas-
matocytes mutant for Croquemort protein are impaired in
their ability to engulf apoptotic cells, but will still recog-
nize and engulf bacteria (Franc et al., 1999). Whether
gcm/gcm2-deficient plasmatocytes will convert into mac-
rophages in response to bacterial invasion or other insults
remains to be explored. The morphology of these cells and
high level of Peroxidasin expression suggest character-
istics of plasmatocytes just before their conversion to
macrophages (Tepass et al., 1994). We suggest a model (Fig.
9) whereby gcm and gcm2 promote the expansion and
differentiation of a Peroxidasin-expressing population of
hemocytes, or “proplasmatocytes.” Expression of gcm and
gcm2 is required for the differentiation of these proplas-
matocytes into plasmatocytes that are competent for
macrophage conversion, and they do so by initiating the
expression of the macrophage receptor Croquemort and
other genes that promote macrophage morphogenesis and
function.
FIG. 9. Model for gcm and gcm2 functions in plasmatocyte differentiation. (A) Wild-type. Hemocyte precursors differentiate into a
population of proplasmatocytes that express Gcm, Gcm2, and Peroxidasin. Gcm and Gcm2 stimulate the proliferation and differentiation
of proplasmatocytes into plasmatocytes that are competent to become macrophages by activating Croquemort and other macrophage genes.
After stage 11, Gcm and Gcm2 expression disappears. Macrophage competent plasmatocytes convert into macrophages in response to
signals from cells undergoing apoptosis. (B) gcm/gcm2. In the absence of Gcm and Gcm2 proteins, proplasmatocytes fail to proliferate.
They express Peroxidasin and partially differentiate into cells with characteristics of plasmatocytes. However, these plasmatocytes are not
competent to convert into macrophages in response to signals from apoptotic cells.
381gcm2 and gcm Promote Macrophage Development
© 2002 Elsevier Science (USA). All rights reserved.
ACKNOWLEDGMENTS
We thank JoMichelle Corrales and Rithwick Rajagopal for the
cloning and initial characterization of the gcm2 cDNA; Melissa
Yee for technical help; Nathalie Franc for Croquemort antisera;
Liselotte Fessler for Peroxidasin antisera; the Bloomington Stock
Center for fly stocks; Ruth Lehmann, Michelle Starz-Gaiano, and
Jones Lab members for comments on the manuscript. This research
was funded in part by the City of New York Council Speaker’s
Fund for Biomedical Research: Toward the Science of Patient Care,
and NIH Grant RO1 NS39373.
REFERENCES
Abrams, J. M., White, K., Fessler, L. I., and Steller, H. (1993).
Programmed cell death during Drosophila embryogenesis. Devel-
opment 117, 29–43.
Adams, M. D., Celniker, S. E., Holt, R. A., Evans, C. A., Gocayne,
J. D., Amanatides, P. G., Scherer, S. E., Li, P. W., Hoskins, R. A.,
Galle, R. F., et al. (2000). The genome sequence of Drosophila
melanogaster. Science 287, 2185–2195.
Akiyama, Y., Hosoya, T., Poole, A. M., and Hotta, Y. (1996). The
gcm-motif: A novel DNA-binding motif conserved in Drosophila
and mammals. Proc. Natl. Acad. Sci. USA 93, 14912–14916.
Akiyama-Oda, Y., Hosoya, T., and Hotta, Y. (1998). Alteration of
cell fate by ectopic expression of Drosophila glial cells missing in
non-neural cells. Dev. Genes Evol. 208, 578–585.
Altschul, S. F., Madden, T. L., Schaffer, A. A., Zhang, J., Zhang, Z.,
Miller, W., and Lipman, D. J. (1997). Gapped BLAST and PSI-
BLAST: A new generation of protein database search programs.
Nucleic Acids Res. 25, 3389–3402.
Altshuller, Y., Copeland, N. G., Gilbert, D. J., Jenkins, N. A., and
Frohman, M. A. (1996). Gcm1, a mammalian homolog of Dro-
sophila glial cells missing. FEBS Lett. 393, 201–204.
Bernardoni, R., Miller, A. A., and Giangrande, A. (1998). Glial
differentiation does not require a neural ground state. Develop-
ment 125, 3189–3200.
Bernardoni, R., Vivancos, B., and Giangrande, A. (1997). glide/gcm
is expressed and required in the scavenger cell lineage. Dev. Biol.
191, 118–130.
Brand, A. H., and Perrimon, N. (1993). Targeted gene expression as
a means of altering cell fates and generating dominant pheno-
types. Development 118, 401–415.
Campbell, G., Goring, H., Lin, T., Spana, E., Andersson, S., Doe, C.
Q, and Tomlinson, A. (1994). RK2, a glial-specific homeodomain
protein required for embryonic nerve cord condensation and
viability in Drosophila. Development 120, 2957–2966.
Crew, J. R., Batterham, P., and Pollock, J. A. (1997). Developing
compound eye in lozenge mutants of Drosophila: Lozenge expres-
sion in the R7 equivalence group. Dev. Genes Evol. 206, 481–493.
Fossett, N., Tevosian, S. G., Gajewski, K., Zhang, Q., Orkin, S. H.,
and Schulz, R. A. (2001). The Friend of GATA proteins U-shaped,
FOG-1, and FOG-2 function as negative regulators of blood,
heart, and eye development in Drosophila. Proc. Natl. Acad. Sci.
USA 98, 7342–7347.
Franc, N. C., Dimarcq, J. L., Lagueux, M., Hoffmann, J., and
Ezekowitz, R. A. (1996). Croquemort, a novel Drosophila
hemocyte/macrophage receptor that recognizes apoptotic cells.
Immunity 4, 431–443.
Franc, N. C., Heitzler, P., Ezekowitz, R. A., and White, K. (1999).
Requirement for croquemort in phagocytosis of apoptotic cells in
Drosophila. Science 284, 1991–1994.
Freeman, M. R., and Doe, C. Q. (2001). Asymmetric Prospero
localization is required to generate mixed neuronal/glial lineages
in the Drosophila CNS. Development 128, 4103–4112.
Halter, D. A., Urban, J., Rickert, C., Ner, S. S., Ito, K., Travers,
A. A., and Technau, G. M. (1995). The homeobox gene repo is
required for the differentiation and maintenance of glia function
in the embryonic nervous system of Drosophila melanogaster.
Development 121, 317–332.
Hosoya, T., Takizawa, K., Nitta, K., and Hotta, Y. (1995). glial cells
missing: A binary switch between neuronal and glial determina-
tion in Drosophila. Cell 82, 1025–1036.
Jones, B. W., Fetter, R. D., Tear, G., and Goodman, C. S. (1995). glial
cells missing: A genetic switch that controls glial versus neuro-
nal fate. Cell 82, 1013–1023.
Kammerer, M., and Giangrande, A. (2001). Glide2, a second glial
promoting factor in Drosophila melanogaster. EMBO J. 20,
4664–4673.
Kim, J., Jones, B. W., Zock, C., Chen, Z., Wang, H., Goodman, C. S.,
and Anderson, D. J. (1998). Isolation and characterization of
mammalian homologs of the Drosophila gene glial cells missing.
Proc. Natl. Acad. Sci. USA 95, 12364–12369.
Klaes, A., Menne, T., Stollewerk, A., Scholz, H., and Klambt, C.
(1994). The Ets transcription factors encoded by the Drosophila
gene pointed direct glial cell differentiation in the embryonic
CNS. Cell 78, 149–160.
Lane, M. E., and Kalderon, D. (1993). Genetic investigation of
cAMP-dependent protein kinase function in Drosophila develop-
ment. Genes Dev. 7, 1229–1243.
Lebestky, T., Chang, T., Hartenstein, V., and Banerjee, U. (2000).
Specification of Drosophila hematopoietic lineage by conserved
transcription factors. Science 288, 146–149.
Liao, G. C., Rehm, E. J., and Rubin, G. M. (2000). Insertion site
preferences of the P transposable element in Drosophila mela-
nogaster. Proc. Natl. Acad. Sci. USA 97, 3347–3351.
Mathey-Prevot, B., and Perrimon, N. (1998). Mammalian and
Drosophila blood: JAK of all trades? Cell 92, 697–700.
Nelson, R. E., Fessler, L. I., Takagi, Y., Blumberg, B., Keene, D. R.,
Olson, P. F., Parker, C. G., and Fessler, J. H. (1994). Peroxidasin:
A novel enzyme-matrix protein of Drosophila development.
EMBO J. 13, 3438–3447.
Patel, N. H. (1994). Imaging neuronal subsets and other cell types in
whole-mount Drosophila embryos and larvae using antibody
probes. Methods Cell Biol. 44, 445–487.
Rehorn, K. P., Thelen, H., Michelson, A. M., and Reuter, R. (1996).
A molecular aspect of hematopoiesis and endoderm development
common to vertebrates and Drosophila. Development 122, 4023–
4031.
Reifegerste, R., Schreiber, J., Gulland, S., Ludemann, A., and
Wegner, M. (1999). mGCMa is a murine transcription factor that
overrides cell fate decisions in Drosophila. Mech. Dev. 82,
141–150.
Rorth, P., Szabo, K., Bailey, A., Laverty, T., Rehm, J., Rubin, G. M.,
Weigmann, K., Milan, M., Benes, V., Ansorge, W., and Cohen,
S. M. (1998). Systematic gain-of-function genetics in Drosophila.
Development 125, 1049–1057.
Rubin, G. M., Hong, L., Brokstein, P., Evans-Holm, M., Frise, E.,
Stapleton, M., and Harvey, D. A. (2000). A Drosophila comple-
mentary DNA resource. Science 287, 2222–2224.
Schmidt, H., Rickert, C., Bossing, T., Vef, O., Urban, J., and
Technau, G. M. (1997). The embryonic central nervous system
382 Alfonso and Jones
© 2002 Elsevier Science (USA). All rights reserved.
lineages of Drosophila melanogaster. II. Neuroblast lineages
derived from the dorsal part of the neuroectoderm. Dev. Biol.
189, 186–204.
Schreiber, J., Enderich, J., and Wegner, M. (1998). Structural re-
quirements for DNA binding of GCM proteins. Nucleic Acids
Res. 26, 2337–2343.
Schreiber, J., Sock, E., and Wegner, M. (1997). The regulator of early
gliogenesis glial cells missing is a transcription factor with a
novel type of DNA-binding domain. Proc. Natl. Acad. Sci. USA
94, 4739–4744.
Tepass, U., Fessler, L. I., Aziz, A., and Hartenstein, V. (1994).
Embryonic origin of hemocytes and their relationship to cell
death in Drosophila. Development 120, 1829–1837.
Tuerk, E. E., Schreiber, J., and Wegner, M. (2000). Protein stability
and domain topology determine the transcriptional activity of
the mammalian glial cells missing homolog, GCMb. J. Biol.
Chem. 275, 4774–4782.
Vincent, S., Vonesch, J. L., and Giangrande, A. (1996). Glide directs
glial fate commitment and cell fate switch between neurones and
glia. Development 122, 131–139.
Wodarz, A., Hinz, U., Engelbert, M., and Knust, E. (1995). Expres-
sion of crumbs confers apical character on plasma membrane
domains of ectodermal epithelia of Drosophila. Cell 82, 67–76.
Xiong, W. C., Okano, H., Patel, N. H., Blendy, J. A., and Montell, C.
(1994). repo encodes a glial-specific homeo domain protein re-
quired in the Drosophila nervous system. Genes Dev. 8, 981–994.
Zinn, K., McAllister, L., and Goodman, C. S. (1988). Sequence
analysis and neuronal expression of fasciclin I in grasshopper and
Drosophila. Cell 53, 577–587.
Received for publication March 22, 2002
Revised May 23, 2002
Accepted May 23, 2002
Published online July 22, 2002
383gcm2 and gcm Promote Macrophage Development
© 2002 Elsevier Science (USA). All rights reserved.
